Spotlight on NOAC reversal

Dr Charles Pollack is an international leader in emergency medicine and was head of the REVERSE-AD trial of idarucizumab (Praxbind), a novel reversal agent for the anticoagulant dabigatran. On the strength of this trial, idarucizumab recently received TGA approval for use in Australian hospitals. To date, it is the only approved reversal agent for a new oral anticoagulant (NOAC).

Dr Pollack, who practises at Philadelphia’s Thomas Jefferson University Hospital, was in Australia this month